Monitor the pace of remaining buyback authorization (~DKK 5.37 billion remaining) for potential acceleration or deceleration in future weekly disclosures. No material impact on valuation or operations from this routine update.
Price Chart
Executive Summary
Novo Nordisk filed a routine 6-K disclosing weekly share repurchase transactions under its existing DKK 15 billion buyback program. Between September 14-18, 2026, the company repurchased 1,090,000 B shares for approximately DKK 303.7 million at an average price of ~DKK 278.5 per share. The program is on track with ~DKK 9.63 billion deployed out of the total authorization since February 2026. This is a routine capital return update with no new strategic or financial information.
Key Facts
- Novo Nordisk repurchased 1,090,000 B shares between Sep 14-18, 2026 for ~DKK 303.7 million
- Total accumulated repurchases under the program: 19,415,000 B shares for DKK 5,829,922,946
- Overall buyback authorization is up to DKK 15 billion over 12 months starting Feb 4, 2026
- As of Sep 18, 2026, total repurchases since Feb 4, 2026: 34,174,179 B shares at avg DKK 281.79 for DKK 9,629,922,935
- Novo Nordisk holds 48,214,876 B shares as treasury shares, representing 1.1% of share capital
Financial Impact
Routine weekly buyback disclosure; ~DKK 303.7 million deployed in the reported week, part of ongoing DKK 15 billion program
Risk Factors
- No material risks identified from this routine buyback disclosure
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006128 |
| Document: 0001171843-26-006128-index-headers.html | 0001171843-26-006128 |
| Document: 0001171843-26-006128-index.html | 0001171843-26-006128 |
| Document: 0001171843-26-006128.txt | 0001171843-26-006128 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 4d ago | 6-K | $39.13 | awaiting T+20 | awaiting T+20 | $39.92 (+2.03%) |
Oct 26, 2026 4d ago | Court Ruling | $38.67 | awaiting T+20 | awaiting T+20 | $39.92 (+3.25%) |
Oct 19, 2026 11d ago | 6-K | $38.42 | awaiting T+20 | awaiting T+20 | $39.92 (+3.92%) |
Oct 13, 2026 17d ago | 6-K | $38.06 | awaiting T+20 | awaiting T+20 | $39.92 (+4.90%) |
Oct 6, 2026 24d ago | 6-K | $37.53 | awaiting T+20 | awaiting T+20 | $39.92 (+6.38%) |
Sep 28, 2026 4w ago | 6-K | $38.71 $38.95 | ▲ +0.61% | ▲ +0.64% | $39.92 (+3.14%) |
Sep 23, 2026 5w ago | Court Ruling | $38.62 $39.43 | ▲ +2.10% | ▲ +2.52% | $39.92 (+3.38%) |
Sep 21, 2026 5w ago | 6-K | $39.80 $38.42 | ▼ −3.47% | ▼ −2.56% | $39.92 (+0.31%) |
Sep 17, 2026 6w ago | 6-K | $43.19 $39.22 | ▼ −9.19% | ▼ −10.40% | $39.92 (−7.56%) |
Sep 15, 2026 6w ago | 6-K | $42.53 $38.06 | ▼ −10.51% | ▼ −13.23% | $39.92 (−6.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers